

Supplementary Table S4. Next-generation sequencing data from screening and Cycle 1 Day 15 tumor biopsy samples.

Patient biopsy sample	MET status (FISH CN)	BOR	Sequencing data with potential (known or likely) functional significance	
			Copy number variant	Short variant
C1D15	Low	SD	None	
C1D15	Low (2.9)	PD	<i>MYC</i> (CN 8), <i>MCL1</i> (CN 9), <i>IKBKE</i> (CN 8)	<i>NRAS</i> (Q61R)
C1D15	Low (2.08)	PD	None	
Screening	Low (3.2)	PD		<i>MSH2</i> (R929*), <i>TP53</i> (L145Q), <i>PTPN11</i> (T468M1)
Screening	High (2.7)	UNK	<i>MCL1</i> (CN 8), <i>MDM4</i> (CN 6), <i>AKT3</i> (CN 7), <i>MYC</i> (CN 13)	<i>BAP1</i> (R60*)
Screening	Low (3.0)	UNK	<i>MCL1</i> (CN 8)	
Screening	Low (5.7)	PD		<i>ASXL1</i> (splice), <i>TP53</i> (R249S), <i>MAP3K13</i> (V257fs*18)
Screening	Low (2.3)	UNK	None	
Screening	High (3.97)	SD	None	
Screening	High	SD		<i>TP53</i> (Y163C)

AKT3, AKT serine/threonine kinase 3; *ASXL1*, additional sex combs like transcriptional regulator 1; *BAP1*, BRCA1-associated protein 1; BOR, best overall response; C1D15, Cycle 1 Day 15; CN, copy number; FISH, fluorescence *in situ* hybridization; *IKBKE*, inhibitor of nuclear factor kappa B kinase subunit epsilon; *MAP3K13*, mitogen-activated protein kinase kinase kinase 13; *MCL1*, myeloid cell leukemia 1; *MDM4*, mouse double minute 4, human homolog; *MSH2*, MutS homolog 2; *MYC*, avian myelocytomatosis viral oncogene homolog; *NRAS*, NRAS proto-oncogene, GTPase; PD, progressive disease; *PTPN11*, protein tyrosine phosphatase, non-receptor type 11; SD, stable disease; *TP53*, tumor protein P53; UNK, unknown.